Mycobacterium kansasii
E928042
Mycobacterium kansasii is a slow-growing, non-tuberculous mycobacterial species that commonly causes pulmonary infections resembling tuberculosis, particularly in immunocompromised individuals.
Statements (52)
| Predicate | Object |
|---|---|
| instanceOf |
acid-fast bacillus
ⓘ
bacterial species ⓘ non-tuberculous mycobacterium ⓘ |
| acidFastStain | Ziehl–Neelsen positive ⓘ |
| cellMorphology | rod-shaped ⓘ |
| clinicalPresentation | tuberculosis-like pulmonary disease ⓘ |
| colonyMorphology | photochromogenic ⓘ |
| cultureMedium |
Lowenstein–Jensen medium
NERFINISHED
ⓘ
Middlebrook 7H10 agar NERFINISHED ⓘ |
| diagnosticMethod |
16S rRNA gene sequencing
ⓘ
bronchoalveolar lavage culture ⓘ line probe assay ⓘ nucleic acid amplification test ⓘ sputum culture ⓘ |
| differentialDiagnosis |
Mycobacterium tuberculosis infection
ⓘ
other non-tuberculous mycobacterial lung disease ⓘ |
| disease |
cavitary lung disease
ⓘ
chronic lung disease ⓘ disseminated infection ⓘ lymphadenitis ⓘ pulmonary infection ⓘ skin and soft tissue infection ⓘ |
| drugResistance | variable resistance to isoniazid ⓘ |
| drugSusceptibility |
usually susceptible to ethambutol
ⓘ
usually susceptible to rifampin ⓘ |
| family | Mycobacteriaceae NERFINISHED ⓘ |
| genus | Mycobacterium NERFINISHED ⓘ |
| geographicDistribution | worldwide ⓘ |
| geographicPrevalence | higher in industrialized countries ⓘ |
| gramStain | Gram-positive ⓘ |
| growthRate | slow-growing ⓘ |
| growthTemperature | optimal around 37 °C ⓘ |
| notTransmittedBy | person-to-person contact ⓘ |
| order | Corynebacteriales NERFINISHED ⓘ |
| oxygenRequirement | aerobic ⓘ |
| pathogenicity | opportunistic pathogen ⓘ |
| phylum | Actinobacteria NERFINISHED ⓘ |
| pigmentProduction | yellow pigment in light ⓘ |
| reservoir |
municipal water systems
ⓘ
natural water sources ⓘ tap water ⓘ |
| riskFactor |
AIDS
NERFINISHED
ⓘ
HIV infection ⓘ chronic obstructive pulmonary disease ⓘ immunosuppression ⓘ silicosis ⓘ |
| taxonRank | species ⓘ |
| transmissionRoute | environmental exposure ⓘ |
| treatment |
ethambutol-containing regimen
ⓘ
isoniazid-containing regimen ⓘ rifampin-based multidrug therapy ⓘ |
| treatmentDuration | at least 12 months after culture conversion ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.